{
  "docId": "019de074-ddab-749d-b286-5e01e8bcb935",
  "docSlug": "f43e68719e672319f390e5844d5bc5fe",
  "documentTitle": "Chimerix | Investor Presentation Deck | 41 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 41,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide details specific inclusion/exclusion criteria including age, mutation status, disease progression, prior therapy, and washout periods.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ddab-749d-b286-5e01e8bcb935/8",
  "deckHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935",
  "deckJsonHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935.json",
  "deckAnchorHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.94,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "list",
      "text": "Eligibility: Age ≥2yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018; Diffuse glioma with a known H3 K27M mutation; Progressive and measurable disease; Prior therapy; Washout periods; Performance status; Corticosteroids; Exclusions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5f55c9e-1c87-45f3-8532-8c37853b8c4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.19
      },
      "kind": "list",
      "text": "Objective: To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc6824bc-3f52-4a2b-afbd-810eb33c6c77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.05
      },
      "kind": "title",
      "text": "FDA-aligned criteria for Phase 2 efficacy analysis to isolate ONC201 single agent activity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfeea1d4-c571-4915-9473-927cb33a3dfa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-protocol",
      "slug": null,
      "matchId": "ed1727b6-74a4-4066-a816-8726f5bf9597",
      "evidence": "Structured presentation of study objective and patient eligibility criteria.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "7df034ba-8b82-48a9-931a-54c9c4d04f47",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents efficacy data for ONC201 in recurrent H3 K27M DMG",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "77a4ca89-6944-4b59-9557-b7e1ac4d70e5",
      "evidence": "The deck presents data on the unmet need and potential benefits of ONC201",
      "position": 0,
      "objective": "Highlight the cost of inaction in treating H3 K27M-mutant diffuse glioma",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}